- Home
- RVT vs XNCR Comparison
RVT vs XNCR Comparison
Compare RVT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVT | XNCR |
|---|---|---|
| Founded | 1986 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | RVT | XNCR |
|---|---|---|
| Price | $17.34 | $24.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 171.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | $5.91 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $14.97 | $10.10 |
| 52 Week High | $19.12 | $30.61 |
Technical Indicators
Market Signals| Indicator | RVT | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 30.00 | 49.49 |
| Support Level | $15.93 | $11.05 |
| Resistance Level | $18.63 | $30.61 |
| Average True Range (ATR) | 0.30 | 1.20 |
| MACD | -0.12 | -0.54 |
| Stochastic Oscillator | 6.04 | 20.02 |
Price Performance
Historical ComparisonAbout RVT Royce Value Trust Inc.
Royce Small-Cap Trust Inc is a diversified closed-end investment company that invests in equity securities of small-cap companies. The company portfolio includes sectors such as Industrials, Financials, Information Technology, Health Care, and Consumer Discretionary.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.